

DR. TANMOY KUMAR MANDAL

Consultant - Medical Oncology

Qualification

MBBS | DTCD | MD (General Medicine) | DM (Medical Oncology) | DNB (Medical Oncology)

Overview

Dr. Tanmoy Kumar Mandal is a renowned consultant in the Medical Oncology Department at Manipal Hospitals in Broadway, Kolkata. With over a decade of extensive experience and expertise in diagnosing and treating cancers, Dr. Mandal has established himself as a leading specialist in this field. Dr. Mandal's academic journey began with his MBBS from NRS Medical College, Kolkata. He then completed his MD in General Medicine from Calcutta National Medical College, Kolkata. His pursuit of excellence continued with a DM in Medical Oncology from Tata Memorial Hospital, Mumbai. Furthering his credentials, Dr. Mandal holds an MRCP in Medical Oncology (Specialty Certificate Examination) and achieved ESMO certification in 2019, marking him as a certified practising consultant medical oncologist. Additionally, he has completed his Diploma in Tuberculosis and Chest Diseases (DTCD) and a DNB in Medical Oncology, further broadening his expertise in respiratory and oncological conditions. He is the Best Medical Oncologist in Kolkata. Dr. Mandal specialises in the treatment of oncological and haematological disorders, expertly managing solid tumours such as gastrointestinal, genitourinary, lung, head and neck,

gynaecological, and breast cancers. Additionally, he is proficient in treating haematological malignancies like acute leukaemias, multiple myeloma, and lymphomas. His clinical skills encompass Chemotherapy, Immunotherapy, Targeted Therapy, and Hormone Therapy for all solid and blood malignancies. Beyond his clinical practice, Dr. Mandal is actively involved in advancing medical knowledge. His research on head and neck cancers, ovarian, and other gastrointestinal disorders has been published in reputable journals, demonstrating his commitment to academic scholarship and innovation. He regularly contributes to medical literature through talks and publications, underscoring his dedication to the field of medical oncology. Fluent in English, Bengali, and Hindi, Dr. Mandal ensures effective communication with his patients, fostering trust and understanding in all interactions. His unwavering dedication to patient care, clinical expertise, and commitment to academic excellence make him a highly respected and renowned specialist in the state

Fellowship & Membership

- European Society of Medical Oncologists (ESMO)
- Indian Society of Medical and Paediatric Oncologists (ISMPO)
- American Society of Clinical Oncologists (ASCO)
- Immune-Oncological Society of India (IOSI)

Field of Expertise

- Specialises in diagnosing and treating various malignant disorders affecting the digestive system, including the oesophagus, stomach, intestines, and associated organs, enhancing patient outcomes.
- Proficient in managing lung cancers using Immunotherapy and effectively handles the associated side effects, ensuring

comprehensive care for his patients.
- Expertise in treating blood cancers such as lymphoma and myeloma using Chemotherapy and Targeted Therapy, providing advanced and personalised treatment options for his patients.

Languages Spoken

- Bengali
- English
- Hindi

Awards & Achievements

- Real-world Eligibility for Treatment-Free Remission in Chronic Myeloid Leukaemia Patients-Report from a Tertiary Cancer Centre in India, presented at the International CML Conference-2017 (iCMLf)
- Long-term and short-term outcomes in patients of chronic myeloid leukaemia treated with generic and innovator imatinib- a retrospective analysis, presented at the International CML Conference-2017 (iCMLf)
- Outcomes of Chronic Myeloid Leukemia-Chronic Phase Patients Treated with Generic Imatinib- Report from Tata Memorial Hospital, oral presentation in Annual meeting of Mumbai Hematology Group, March 2018
- Trastuzumab Emtansine in HER2 positive metastatic breast cancer: A real-world experience, E poster in ASCO- 2018, ASCO Abstract #226633
- Chemotherapy-Induced Anemia / Zydus Cadila- Desidustat, Phase 1, Principal Investigator, 2021 - Clinical Trial
- Non-small cell lung carcinoma / Pfizer- ICON PLC- Dacomitinib,

Phase 4, Principal Investigator, 2021- Ongoing Clinical Trial

- Breast / Ovarian / Prostate Cancer (NATCO Pharma / CBCC Global)- Olaparib, BA/BE, Principal Investigator, 2021 - Ongoing
- Prostate Cancer/ Pfizer- ICON PLC- Talazoparib, Phase 3, Principal Investigator, 2021
- Renal Cell Carcinoma/ Axis Clinicals- Sunitinib, BA/BE, Principal Investigator, 2021- Ongoing
- Relapsed multiple myeloma- Carfilzomib- Amgen, Phase 4, Principal Investigator, 2021- Ongoing
- SPEAR Registry- Novartis- PIK3CA testing observational, Principal Investigator, 2021- Ongoing

Talks & Publications

- RMAC study: A randomized study for evaluation of metronomic adjuvant chemotherapy in recurrent head and neck cancers post salvage surgical resection in those who are ineligible for re-irradiation, Oral Oncology, Volume 128,2022,105816, ISSN 1368-8375, https://doi.org/10.1016/j.oraloncology.2022.105816
- Osteosarcoma journey over two decades in India: Small steps, big changes- Pediatric Blood Cancer. 2019;66:e27877. https://doi.org/10.1002/pbc.27877
- Influence of hypothyroidism post chemoradiation on outcomes in head and neck cancer- DOI: 10.1200/JCO.2018.36.15_suppl.e18066 Journal of Clinical Oncology 36, no. 15_suppl. Published online June 01, 2018
- Demography and pattern of care of patients with head-and-neck carcinoma: Experience from a tertiary care centre in North India- DOI: 10.4103/crst.crst_286_20
- Outcomes of Patients with Splenic Marginal Zone Lymphoma Treated with Rituximab or Splenectomy: Report from Tertiary Cancer Center in India- DOI:

https://doi.org/10.1016/j.clml.2018.07.216

- Patil VM, Noronha V, Joshi A, Mandal TK, Bhattacharjee A, Goel A, et al. Hypothyroidism post-chemoradiation on outcomes in head-and-neck cancer. Cancer Res Stat Treat 2018; 1:84-91. https://www.crstonline.com/text.asp?2018/1/2/84/258535
- Choudhary, A.K., Abraham, G., Patil, V.M. et al. Audit of Demographics, Treatment Patterns and Outcomes of Differentiated Thyroid Cancers Treated with Tyrosine Kinase Inhibitors. Indian J Surg Oncol (2021). https://doi.org/10.1007/s13193-021-01445-y
- Mandal TK, Roy S, Singh S, Lali BS, Chowdhury Z, Nayak L. Blastic plasmacytoid dendritic cell neoplasm of the thigh: A case report and narrative review of the literature. Cancer Res Stat Treat [serial online] 2020 [cited 2021 Dec 8]; 3:630-4. Available from: https://www.crstonline.com/text.asp?2020/3/3/630/295540
- Srinivas S, Roy S, Mandal TK, Das S. A Varanasi experience. Cancer Res Stat Treat [serial online] 2020 [cited 2021 Dec 8];3:160-1. Available from: https://www.crstonline.com/text.asp?2020/3/1/160/279083
- Kanteti, A.P.K., Abraham, G., Patil, V.M. et al. An Audit of Systemic Therapy in Medullary Carcinoma Thyroid. Indian J Surg Oncol (2021) https://doi.org/10.1007/s13193-021-01381-x
- Roy S, Mandal TK, Nayak L, Gupta A, Shetty DL. Primary osseous burkitt lymphoma mimicking multiple myeloma – A case report and review of the literature. J Appl Hematol [serial online] 2021 [cited 2021 Dec 8];12:37-40. Available from: https://www.jahjournal.org/text.asp?2021/12/1/37/311324
- Venetoclax – The Game-changer in Hematology- CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(04): 555-558. DOI: 10.4103/ijmpo.ijmpo_260_20
- Cutaneous Involvement of Systemic Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma- CC BY-NC-ND

4.0 · Indian J Med Paediatr Oncol 2020; 41(02): 239-240. DOI: 10.4103/ijmpo.ijmpo_72_20

- Splenic marginal zone lymphoma relapsing as miliary lung mottling: an unusual presentation- DOI: https://doi.org/10.5045/br.2018.53.2.103
- Subarachnoid haemorrhage caused by Moya Moya disease with no intracranial aneurysm-A rare case report. Indian Medical Journal, Volume-108, 15 December 2014 Annexure. pISSN No.-0091-5871
- A case of Disseminated NCC infection as Immune Reconstitution Inflammatory Syndrome in an HIV patient"- Indian Medical Journal, Volume-108, 15 September 2014 Annexure. pISSN No.-0091-5871